Role of Novel Oral Anticoagulants in Coronary Intervention

doi:N/A

Bangaldesh Journal of Cardivascular Medicine

2026, Volume 4, Issue 2 : 1-4

Research Article

Role of Novel Oral Anticoagulants in Coronary Intervention

Jonathan Miller

Sarah Khan

Ahmed Rahman

Emily Carter

⁴

Department of Interventional Cardiology, Global Heart Institute, Boston, USA

Division of Cardiovascular Medicine, University Medical Center, London, UK

Department of Cardiology, National Cardiovascular Hospital, Dubai, UAE

⁴

Department of Clinical Research, International Cardiac Sciences Centre, Sydney, Australia

Abstract

Background: Novel oral anticoagulants, also called direct oral anticoagulants, have transformed antithrombotic management in patients undergoing percutaneous coronary intervention, especially those with atrial fibrillation requiring long-term anticoagulation.

Objective: To evaluate the role, safety, and clinical effectiveness of NOAC-based antithrombotic strategies in patients undergoing coronary intervention.

Methods: This review-style research article summarizes contemporary evidence regarding apixaban, rivaroxaban, dabigatran, and edoxaban in PCI patients, with emphasis on bleeding, ischemic events, stent thrombosis, and optimal therapy duration.

Results: NOAC-based dual therapy, generally consisting of a NOAC plus a P2Y12 inhibitor, reduces bleeding compared with traditional warfarin-based triple therapy. Ischemic outcomes are broadly comparable in selected patients, although early aspirin use may be considered in patients with high thrombotic risk.

Conclusion: NOACs have become central to antithrombotic strategies after PCI in patients requiring long-term anticoagulation. Individualized balancing of bleeding and ischemic risk is essential.

Keywords

Novel oral anticoagulants

Direct oral anticoagulants

PCI

Atrial fibrillation

Dual antithrombotic therapy

Coronary stenting

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.

Bangladesh J. Cardiovasc. Med. open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.

Recommended Articles

Drug-Coated Balloons in Peripheral Vascular Interventions

Michael R. Anderson,

Sarah T. Bennett,

Ahmed K. Rahman,

Priya Sharma,

David L. Cooper

1-6

Implantable Cardioverter Defibrillator Outcomes in South Asian Populations

Arvind K. Mehta,

Farhana R. Siddiqui,

Michael J. Carter,